Marker Therapeutics Stock Fundamentals
| MRKR Stock | USD 1.24 0.06 5.08% |
Marker Therapeutics fundamentals help investors to digest information that contributes to Marker Therapeutics' financial success or failures. It also enables traders to predict the movement of Marker Stock. The fundamental analysis module provides a way to measure Marker Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marker Therapeutics stock.
Marker |
Marker Therapeutics Company Return On Asset Analysis
Marker Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Marker Therapeutics Return On Asset | -0.42 |
Most of Marker Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marker Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Marker Therapeutics has a Return On Asset of -0.4192. This is 95.21% lower than that of the Biotechnology sector and 98.22% lower than that of the Health Care industry. The return on asset for all United States stocks is 199.43% higher than that of the company.
Marker Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marker Therapeutics's current stock value. Our valuation model uses many indicators to compare Marker Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marker Therapeutics competition to find correlations between indicators driving Marker Therapeutics's intrinsic value. More Info.Marker Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Marker Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Marker Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marker Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics of similar companies.Marker Therapeutics is currently under evaluation in return on asset category among its peers.
Marker Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (1.25) % | ||||
| Current Valuation | (3.13 M) | ||||
| Shares Outstanding | 10.71 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 41.78 % | ||||
| Number Of Shares Shorted | 149.81 K | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 2.01 X | ||||
| Price To Sales | 2.34 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (5.6 M) | ||||
| EBITDA | (11.79 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 3.07 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Short Ratio | 1.80 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 10.33 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 12.64 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
| Net Asset | 17.13 M |
About Marker Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marker Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company was founded in 1999 and is headquartered in Houston, Texas. Marker Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.